Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $16.56 and last traded at $16.56, with a volume of 213 shares. The stock had previously closed at $16.71.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on FLGT shares. Piper Sandler cut their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating for the company in a report on Monday, November 11th. StockNews.com raised Fulgent Genetics from a "sell" rating to a "hold" rating in a report on Tuesday.
Check Out Our Latest Stock Report on Fulgent Genetics
Fulgent Genetics Stock Up 1.7 %
The stock has a 50-day moving average of $20.59 and a 200 day moving average of $21.35. The stock has a market cap of $520.03 million, a PE ratio of -3.03 and a beta of 1.51.
Insider Transactions at Fulgent Genetics
In related news, CEO Ming Hsieh sold 2,313 shares of the firm's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $52,805.79. Following the completion of the sale, the chief executive officer now directly owns 707,275 shares in the company, valued at approximately $16,147,088.25. This trade represents a 0.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 4,324 shares of company stock worth $98,717 in the last quarter. Company insiders own 32.66% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Asset Dedication LLC acquired a new stake in Fulgent Genetics during the second quarter worth $33,000. nVerses Capital LLC purchased a new stake in Fulgent Genetics in the 2nd quarter valued at about $43,000. Signaturefd LLC lifted its position in Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company's stock valued at $44,000 after buying an additional 1,132 shares during the last quarter. Point72 DIFC Ltd purchased a new position in Fulgent Genetics during the third quarter worth about $46,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Fulgent Genetics during the second quarter valued at about $63,000. 48.06% of the stock is currently owned by institutional investors and hedge funds.
About Fulgent Genetics
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Read More
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
